Literature DB >> 6287931

Pharmacokinetics and tolerance of ceftriaxone in humans after single-dose intramuscular administration in water and lidocaine diluents.

I H Patel, R E Weinfeld, J Konikoff, M Parsonnet.   

Abstract

The effects of 1% lidocaine as a diluent on the pharmacokinetics and tolerance of ceftriaxone administered intramuscularly were investigated in 12 adult volunteers. Each subject received two 0.5-g doses of ceftriaxone (one in water and the other in 1% lidocaine) at least 1 week apart in a randomized crossover fashion. Plasma and urine samples were collected serially and assayed for ceftriaxone content by high-performance liquid chromatography. The mean peak plasma concentration, time to attain the peak, area under the plasma curve from time zero to infinity, and elimination half-life were 45 micrograms/ml, 2.5 h, 578 micrograms . h/ml, and 7.1 h, respectively, after intramuscular administration of ceftriaxone in water diluent. The corresponding mean values in 1% lidocaine diluent were 42 micrograms/ml, 3 h, 577 micrograms . h/ml, and 7.0 h. The pharmacokinetic data suggested that 1% lidocaine does not alter either the elimination parameters or the bioavailability of intramuscularly administered ceftriaxone. The intensity and frequency of pain at the injection site were reduced considerably by the coadministered lidocaine.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6287931      PMCID: PMC182052          DOI: 10.1128/AAC.21.6.957

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Intramuscular injection of drugs.

Authors:  D J Greenblatt; J Koch-Weser
Journal:  N Engl J Med       Date:  1976-09-02       Impact factor: 91.245

2.  A pharmacokinetic and tolerance study of Ro13-9904, a new cephalosporin antibiotic.

Authors:  M E Pickup; H A Bird; J R Lowe; L Lees; V Wright
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335

3.  Multiple intravenous dose pharmacokinetics of ceftriaxone in man.

Authors:  I H Patel; K Miller; R Weinfeld; J Spicehandler
Journal:  Chemotherapy       Date:  1981       Impact factor: 2.544

4.  Pharmacokinetics of Rocephin, a highly active new cephalosporin with an exceptionally long biological half-life.

Authors:  K Stoeckel
Journal:  Chemotherapy       Date:  1981       Impact factor: 2.544

5.  Effect of lidocaine on the absorption, disposition and tolerance of intramuscularly administered cefoxitin.

Authors:  P F Sonneville; K S Albert; H Skeggs; H Gentner; K C Kwan; C M Martin
Journal:  Eur J Clin Pharmacol       Date:  1977-12-02       Impact factor: 2.953

Review 6.  Clinical pharmacokinetics of lignocaine.

Authors:  N L Benowitz; W Meister
Journal:  Clin Pharmacokinet       Date:  1978 May-Jun       Impact factor: 6.447

7.  Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin.

Authors:  M Seddon; R Wise; A P Gillett; R Livingston
Journal:  Antimicrob Agents Chemother       Date:  1980-08       Impact factor: 5.191

8.  Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics.

Authors:  K Stoeckel; P J McNamara; R Brandt; H Plozza-Nottebrock; W H Ziegler
Journal:  Clin Pharmacol Ther       Date:  1981-05       Impact factor: 6.875

9.  Bioavailability and pain study of cefamandole nafate.

Authors:  T S Foster; R P Shrewsbury; J D Coonrod
Journal:  J Clin Pharmacol       Date:  1980 Aug-Sep       Impact factor: 3.126

10.  Pharmacokinetics of ceftriaxone in humans.

Authors:  I H Patel; S Chen; M Parsonnet; M R Hackman; M A Brooks; J Konikoff; S A Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

View more
  24 in total

Review 1.  Challenges Associated with Route of Administration in Neonatal Drug Delivery.

Authors:  Matthew W Linakis; Jessica K Roberts; Anita C Lala; Michael G Spigarelli; Natalie J Medlicott; David M Reith; Robert M Ward; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

2.  Investigation of bioequivalence and tolerability of intramuscular ceftriaxone injections by using 1% lidocaine, buffered lidocaine, and sterile water diluents.

Authors:  C J Hayward; A N Nafziger; S J Kohlhepp; J S Bertino
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

3.  Can Lidocaine be Safely Used to Reduce Pain Caused by Intramuscular Penicillin Injections? A Short Literature Review.

Authors:  Amir Emami Zeydi; Hadi Darvishi Khezri
Journal:  Oman Med J       Date:  2012-07

4.  Reversing the myths obstructing the determination of optimal age- and disease-based drug dosing in pediatrics.

Authors:  Michael D Reed
Journal:  J Pediatr Pharmacol Ther       Date:  2011-01

5.  Randomised observer blind comparative trial of ceftriaxone and penicillin in treating uncomplicated gonorrhoea in men and women.

Authors:  C A Dixon; J B Bittiner; M Shahidullah; R C Slack; M Z Sulaiman
Journal:  Genitourin Med       Date:  1986-04

6.  Validation and Application of a Dried Blood Spot Ceftriaxone Assay.

Authors:  Madhu Page-Sharp; Troy Nunn; Sam Salman; Brioni R Moore; Kevin T Batty; Timothy M E Davis; Laurens Manning
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

7.  Crossover study of the pharmacokinetics of ceftriaxone administered intravenously or intramuscularly to healthy volunteers.

Authors:  B R Meyers; E S Srulevitch; J Jacobson; S Z Hirschman
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

Review 8.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

9.  Pharmacokinetics of cefotiam administered intravenously and intramuscularly to healthy adults.

Authors:  A M Brisson; A Bryskier; L Millerioux; J B Fourtillan
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

Review 10.  Beta-lactams in sexually transmitted diseases: rationale for selection and dosing regimens.

Authors:  D Kunimoto; R Brunham; A Ronald
Journal:  Eur J Clin Microbiol       Date:  1984-12       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.